Days 1-3: Possible early reduction in inflammation and background pain Days 4-7: Noticeable decrease in pain intensity for many users Weeks 2-3: Improved grip strength and reduced activity-related pain Weeks 4-6: Significant functional improvement
22 Based on the favorable bioavailability of the amide, N-acetylcysteine amide (NACA), over the acid, NAC, 23 and likely its methyl ester, 24 the pursuit of NACA therapy for treatment of HCCAA is warranted
Further, batch-specific analytical testing, including mass spectrometry, is performed in partnership with independent analytical labs to verify identity, composition, and consistency across production lots
A value-based care model aligns provider incentives with these realities, rewarding clinics that keep patients engaged and progressing rather than simply cycling through consultations